DIVISLAB - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.0
| Stock Code | DIVISLAB | Market Cap | 1,72,621 Cr. | Current Price | 6,502 ₹ | High / Low | 7,078 ₹ |
| Stock P/E | 67.1 | Book Value | 578 ₹ | Dividend Yield | 0.46 % | ROCE | 20.6 % |
| ROE | 15.6 % | Face Value | 2.00 ₹ | DMA 50 | 6,220 ₹ | DMA 200 | 6,216 ₹ |
| Chg in FII Hold | 0.21 % | Chg in DII Hold | -0.05 % | PAT Qtr | 653 Cr. | PAT Prev Qtr | 696 Cr. |
| RSI | 66.1 | MACD | 103 | Volume | 3,93,137 | Avg Vol 1Wk | 3,35,462 |
| Low price | 5,636 ₹ | High price | 7,078 ₹ | PEG Ratio | -7.29 | Debt to equity | 0.01 |
| 52w Index | 60.1 % | Qtr Profit Var | 9.88 % | EPS | 94.8 ₹ | Industry PE | 30.1 |
📊 DIVISLAB is trading above both its 50 DMA (6,220 ₹) and 200 DMA (6,216 ₹), confirming short-term bullish strength. RSI at 66.1 indicates strong momentum nearing overbought territory, while MACD at 103 shows positive divergence. Current volume (3,93,137) is above average (3,35,462), suggesting strong participation. Bollinger Bands show price near the upper band, pointing to resistance around 6,550–6,600 ₹.
🎯 Entry Zone: 6,400 ₹ – 6,500 ₹ (support near DMA levels)
💰 Exit Zone: 6,550 ₹ – 6,600 ₹ (resistance band)
🔄 Trend Status: Trending upward with strong momentum, but caution warranted due to overbought signals and earnings pressure.
Positive
- Price trading above both 50 DMA and 200 DMA confirms bullish bias.
- Strong ROE (15.6%) and ROCE (20.6%) highlight solid fundamentals.
- EPS of 94.8 ₹ supports valuation consistency.
- Virtually debt-free balance sheet (debt-to-equity 0.01).
- FII holdings increased (+0.21%), reflecting foreign investor confidence.
Limitation
- High P/E (67.1) compared to industry PE (30.1) signals overvaluation risk.
- PEG ratio (-7.29) reflects poor growth-adjusted valuation.
- Quarterly PAT decline (696 Cr → 653 Cr) highlights earnings pressure.
- RSI nearing overbought levels signals risk of short-term correction.
Company Negative News
- Sequential PAT decline highlights earnings volatility.
- DII holdings decreased (-0.05%), showing reduced domestic institutional support.
Company Positive News
- Quarterly profit variation (+9.88%) highlights resilience despite sequential decline.
- FII inflows show confidence in long-term growth prospects.
Industry
- Industry PE at 30.1 is much lower than DIVISLAB’s 67.1, highlighting premium valuation.
- Pharmaceutical sector remains resilient with long-term demand but faces margin pressures.
Conclusion
⚖️ DIVISLAB is trending upward with strong technical momentum supported by fundamentals. Entry near 6,400–6,500 ₹ offers favorable positioning, with exits around 6,550–6,600 ₹. While momentum is strong, stretched valuations and earnings pressure warrant disciplined risk management for traders and investors.
This is the short-term technical trade view. If you’d like, I can also prepare a sector overlay benchmarking DIVISLAB against pharma peers to refine entry/exit strategies for your workflow reports.